QHeart Medical is a clinical trial stage medical device company commercializing patented extra aortic balloon counterpulsation technology that is fully implantable and requires no pump or controller to operate. The product targets both preserved and unpreserved ejection fraction hypertensive heart failure, that's 18 million indicated of the 50 million with heart failure world wide, and 350 million unserved drug resistant hypertension indicated of the 1.4 billion globally with hypertension.